<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02301416</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00027047</org_study_id>
    <nct_id>NCT02301416</nct_id>
  </id_info>
  <brief_title>Qsymia as an Adjunct to Surgical Therapy in the Superobese</brief_title>
  <official_title>Qsymia as an Adjunct to Surgical Therapy in the Superobese</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wake Forest University Health Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>VIVUS, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Wake Forest University Health Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study tests the efficacy of the medication, Qsymia, as an adjunct therapy in superobese
      individuals planning to undergo weight loss surgery. Individuals taking the medication before
      and after surgery will be compared to historical controls who had surgery without taking the
      medication.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      While there is obvious focus on the obesity epidemic that affects approximately one-third of
      the U.S. population, one subgroup within the epidemic remains on the fringe of scientific
      study and effective treatment options. The super obese patient, in this instance defined as
      those with a BMI ≥ 50 kg/m2, presents a difficult treatment challenge in managing this level
      of obesity. While bariatric surgery, including Roux-en-Y gastric bypass and biliopancreatic
      diversion with duodenal switch, have been shown to be effective in severe obesity (BMI ≥ 40
      kg/m2), the risks involved with surgical intervention in the super obese patient are high.

      Qsymia provides a potential opportunity to develop an effective treatment plan that would be
      an adjunct to surgical intervention in the super obese patient. Use of Qsymia in addition to
      a low-calorie dietary prescription pre-operatively would effectively decrease weight prior to
      surgical intervention, lowering surgical risk to some extent. Additionally, if continued
      post-operatively, Qsymia as an adjunct to the post-surgical dietary plan would potentially
      extend the weight loss horizon so that the probability of the typical weight loss plateau at
      12-18 months is decreased.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 2014</start_date>
  <completion_date type="Actual">June 27, 2018</completion_date>
  <primary_completion_date type="Actual">June 27, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of Patients Who do Not Meet the Criteria to Move Forward With Roux en Y Gastric Bypass (RYGB)</measure>
    <time_frame>24 months post-operatively</time_frame>
    <description>Proportion of patients who do not meet the criteria to move forward with a second surgical procedure following an initial procedure plus the medication Qsymia. The criteria that suggest RYGB is indicated are: 1) BMI of 40 or greater or 2) BMI of 35-39.9 with poorly controlled co-morbidities.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent Weight Change</measure>
    <time_frame>Pre-operatively and 24 months post-operatively</time_frame>
    <description>Percent weight loss achieved before and after surgery while taking the medication, Qsymia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body Mass Index</measure>
    <time_frame>24 months post-operatively</time_frame>
    <description>Resulting body mass index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Body Fat</measure>
    <time_frame>24 months post-operatively</time_frame>
    <description>Change in percent body fat</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Resting Metabolic Rate</measure>
    <time_frame>24 months post-operatively</time_frame>
    <description>Resting metabolic rate via indirect calorimetry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Weight Change</measure>
    <time_frame>Pre-operatively and 12 months post-operatively</time_frame>
    <description>Percent weight loss achieved before and after surgery while taking the medication, Qsymia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Weight Change</measure>
    <time_frame>Pre-operatively and 6 months post-operatively</time_frame>
    <description>Percent weight loss achieved before and after surgery while taking the medication, Qsymia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Weight Change</measure>
    <time_frame>Pre-operatively and 3 months post-operatively</time_frame>
    <description>Percent weight loss achieved before and after surgery while taking the medication, Qsymia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body Mass Index</measure>
    <time_frame>12 months post-operatively</time_frame>
    <description>Resulting body mass index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body Mass Index</measure>
    <time_frame>6 months post-operatively</time_frame>
    <description>Resulting body mass index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body Mass Index</measure>
    <time_frame>3 months post-operatively</time_frame>
    <description>Resulting body mass index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Body Fat</measure>
    <time_frame>12 months post-operatively</time_frame>
    <description>Change in percent body fat</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Body Fat</measure>
    <time_frame>6 months post-operatively</time_frame>
    <description>Change in percent body fat</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Body Fat</measure>
    <time_frame>3 months post-operatively</time_frame>
    <description>Change in percent body fat</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Resting Metabolic Rate</measure>
    <time_frame>12 months post-operatively</time_frame>
    <description>Resting metabolic rate via indirect calorimetry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Resting Metabolic Rate</measure>
    <time_frame>6 months post-operatively</time_frame>
    <description>Resting metabolic rate via indirect calorimetry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Resting Metabolic Rate</measure>
    <time_frame>3 months post-operatively</time_frame>
    <description>Resting metabolic rate via indirect calorimetry</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Obesity</condition>
  <condition>Metabolic Surgery</condition>
  <condition>Weight Loss</condition>
  <condition>Bariatric Surgery Procedures</condition>
  <arm_group>
    <arm_group_label>Phentermine/topiramate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects enrolled in the study will be placed on the study medication.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Historical Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Historical controls who had sleeve gastrectomy during the same time frame without phentermine/topiramate treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Phentermine/topiramate</intervention_name>
    <description>Minimum of 3 months on Qsymia (7.5/46 mg) prior to scheduled weight loss surgery and continuance of up to 24 months of Qsymia after scheduled weight loss surgery.</description>
    <arm_group_label>Phentermine/topiramate</arm_group_label>
    <other_name>Qsymia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>low calorie diet</intervention_name>
    <description>The low-calorie diet will be individually tailored based on initial resting metabolic rate measurement and co-morbid conditions.</description>
    <arm_group_label>Phentermine/topiramate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  BMI ≥ 50 kg/m2

          -  Determined to be a good candidate for surgery based on medical and psychological exam.

          -  Willing to participate in a 3-6 month medically supervised weight loss plan prior to
             surgery.

          -  Planning to remain in the reasonable vicinity of the Wake Forest Baptist Health -
             Weight Management Center for the duration of the study.

        Exclusion Criteria:

          -  History of prior weight loss surgery (removal/conversion from band to sleeve will not
             be excluded)

          -  Pregnant (women of childbearing potential will complete a pregnancy test (blood draw)
             to make sure they are not pregnant at the time that they initiate the medication).
             Ongoing monitoring of pregnancy status is the responsibility of the patient and they
             are instructed as such in the consent form.

          -  Ongoing use of weight loss medication

          -  Contraindications to use of Qsymia, including pregnancy, history of glaucoma, unstable
             cardiac disease (unstable angina, recent heart attack or stroke (in the past 6
             months), uncontrolled arrhythmia), hyperthyroidism, taking monoamine oxidase
             inhibitors (MAOIs) or allergy to either topiramate or sympathomimetic amines like
             phentermine.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jamy D Ard, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wake Forest University Health Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Wake Forest Baptist Health</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>November 21, 2014</study_first_submitted>
  <study_first_submitted_qc>November 24, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 25, 2014</study_first_posted>
  <results_first_submitted>July 5, 2019</results_first_submitted>
  <results_first_submitted_qc>August 12, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">September 4, 2019</results_first_posted>
  <last_update_submitted>August 12, 2019</last_update_submitted>
  <last_update_submitted_qc>August 12, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Weight Loss</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Topiramate</mesh_term>
    <mesh_term>Phentermine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 28, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/16/NCT02301416/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Retrospective chart review patients were not considered enrolled, but historical data was used as a comparison so it is included.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Phentermine/Topiramate</title>
          <description>All subjects enrolled in the study will be placed on the study medication.
Phentermine/topiramate: Minimum of 3 months on Qsymia (7.5/46 mg) prior to scheduled weight loss surgery and continuance of up to 24 months of Qsymia after scheduled weight loss surgery.</description>
        </group>
        <group group_id="P2">
          <title>Historical Control</title>
          <description>Retrospective chart review of patients who had sleeve gastrectomy without phentermine/topiramate</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Phentermine/Topiramate</title>
          <description>All subjects enrolled in the study will be placed on the study medication.
Phentermine/topiramate: Minimum of 3 months on Qsymia (7.5/46 mg) prior to scheduled weight loss surgery and continuance of up to 24 months of Qsymia after scheduled weight loss surgery.</description>
        </group>
        <group group_id="B2">
          <title>Surgery Only</title>
          <description>Historical controls who had sleeve gastrectomy without phentermine/topiramate</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
            <count group_id="B2" value="40"/>
            <count group_id="B3" value="55"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43.4" spread="7.3"/>
                    <measurement group_id="B2" value="45" spread="10.8"/>
                    <measurement group_id="B3" value="44.6" spread="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="45"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="55"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="03"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="43"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body weight</title>
          <units>kilograms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="178.9" spread="31.1"/>
                    <measurement group_id="B2" value="159.5" spread="21"/>
                    <measurement group_id="B3" value="164.8" spread="25.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body mass index</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.2" spread="7.1"/>
                    <measurement group_id="B2" value="57" spread="5.6"/>
                    <measurement group_id="B3" value="58.1" spread="6.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Proportion of Patients Who do Not Meet the Criteria to Move Forward With Roux en Y Gastric Bypass (RYGB)</title>
        <description>Proportion of patients who do not meet the criteria to move forward with a second surgical procedure following an initial procedure plus the medication Qsymia. The criteria that suggest RYGB is indicated are: 1) BMI of 40 or greater or 2) BMI of 35-39.9 with poorly controlled co-morbidities.</description>
        <time_frame>24 months post-operatively</time_frame>
        <population>2 participants had RYGB instead of Sleeve Gastrectomy</population>
        <group_list>
          <group group_id="O1">
            <title>Phentermine/Topiramate</title>
            <description>All subjects enrolled in the study will be placed on the study medication.
Phentermine/topiramate: Minimum of 3 months on Qsymia (7.5/46 mg) prior to scheduled weight loss surgery and continuance of up to 24 months of Qsymia after scheduled weight loss surgery.</description>
          </group>
          <group group_id="O2">
            <title>Surgery Only</title>
            <description>Historical controls who had surgery only</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients Who do Not Meet the Criteria to Move Forward With Roux en Y Gastric Bypass (RYGB)</title>
          <description>Proportion of patients who do not meet the criteria to move forward with a second surgical procedure following an initial procedure plus the medication Qsymia. The criteria that suggest RYGB is indicated are: 1) BMI of 40 or greater or 2) BMI of 35-39.9 with poorly controlled co-morbidities.</description>
          <population>2 participants had RYGB instead of Sleeve Gastrectomy</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Weight Change</title>
        <description>Percent weight loss achieved before and after surgery while taking the medication, Qsymia.</description>
        <time_frame>Pre-operatively and 24 months post-operatively</time_frame>
        <population>2 participants had RYGB instead of sleeve gastrectomy</population>
        <group_list>
          <group group_id="O1">
            <title>Phentermine/Topiramate</title>
            <description>All subjects enrolled in the study will be placed on the study medication.
Phentermine/topiramate: Minimum of 3 months on Qsymia (7.5/46 mg) prior to scheduled weight loss surgery and continuance of up to 24 months of Qsymia after scheduled weight loss surgery.</description>
          </group>
          <group group_id="O2">
            <title>Surgery Only</title>
            <description>Historical controls who had surgery only</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Weight Change</title>
          <description>Percent weight loss achieved before and after surgery while taking the medication, Qsymia.</description>
          <population>2 participants had RYGB instead of sleeve gastrectomy</population>
          <units>Percentage of weight change</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-38.16" lower_limit="-45.39" upper_limit="-30.94"/>
                    <measurement group_id="O2" value="-27" lower_limit="-31.02" upper_limit="-22.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Body Mass Index</title>
        <description>Resulting body mass index</description>
        <time_frame>24 months post-operatively</time_frame>
        <population>2 participants had RYGB instead of Sleeve gastrectomy</population>
        <group_list>
          <group group_id="O1">
            <title>Phentermine/Topiramate</title>
            <description>All subjects enrolled in the study will be placed on the study medication.
Phentermine/topiramate: Minimum of 3 months on Qsymia (7.5/46 mg) prior to scheduled weight loss surgery and continuance of up to 24 months of Qsymia after scheduled weight loss surgery.</description>
          </group>
          <group group_id="O2">
            <title>Surgery Only</title>
            <description>Historical controls who had surgery only</description>
          </group>
        </group_list>
        <measure>
          <title>Body Mass Index</title>
          <description>Resulting body mass index</description>
          <population>2 participants had RYGB instead of Sleeve gastrectomy</population>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.79" lower_limit="29.47" upper_limit="38.12"/>
                    <measurement group_id="O2" value="41.96" lower_limit="39.47" upper_limit="44.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Body Fat</title>
        <description>Change in percent body fat</description>
        <time_frame>24 months post-operatively</time_frame>
        <population>Measure not obtained</population>
        <group_list>
          <group group_id="O1">
            <title>Phentermine/Topiramate</title>
            <description>All subjects enrolled in the study will be placed on the study medication.
Phentermine/topiramate: Minimum of 3 months on Qsymia (7.5/46 mg) prior to scheduled weight loss surgery and continuance of up to 24 months of Qsymia after scheduled weight loss surgery.</description>
          </group>
          <group group_id="O2">
            <title>Historical Control</title>
            <description>Historical controls who had sleeve gastrectomy during the same time frame without phentermine/topiramate treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Body Fat</title>
          <description>Change in percent body fat</description>
          <population>Measure not obtained</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Resting Metabolic Rate</title>
        <description>Resting metabolic rate via indirect calorimetry</description>
        <time_frame>24 months post-operatively</time_frame>
        <population>Outcome measure not obtained</population>
        <group_list>
          <group group_id="O1">
            <title>Phentermine/Topiramate</title>
            <description>All subjects enrolled in the study will be placed on the study medication.
Phentermine/topiramate: Minimum of 3 months on Qsymia (7.5/46 mg) prior to scheduled weight loss surgery and continuance of up to 24 months of Qsymia after scheduled weight loss surgery.</description>
          </group>
          <group group_id="O2">
            <title>Surgery Only</title>
            <description>Historical controls who had surgery only</description>
          </group>
        </group_list>
        <measure>
          <title>Resting Metabolic Rate</title>
          <description>Resting metabolic rate via indirect calorimetry</description>
          <population>Outcome measure not obtained</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Weight Change</title>
        <description>Percent weight loss achieved before and after surgery while taking the medication, Qsymia.</description>
        <time_frame>Pre-operatively and 12 months post-operatively</time_frame>
        <population>2 participants had RYGB instead of sleeve gastrectomy</population>
        <group_list>
          <group group_id="O1">
            <title>Phentermine/Topiramate</title>
            <description>All subjects enrolled in the study will be placed on the study medication.
Phentermine/topiramate: Minimum of 3 months on Qsymia (7.5/46 mg) prior to scheduled weight loss surgery and continuance of up to 24 months of Qsymia after scheduled weight loss surgery.</description>
          </group>
          <group group_id="O2">
            <title>Surgery Only</title>
            <description>Historical controls who had surgery only</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Weight Change</title>
          <description>Percent weight loss achieved before and after surgery while taking the medication, Qsymia.</description>
          <population>2 participants had RYGB instead of sleeve gastrectomy</population>
          <units>Percent</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-39.34" lower_limit="-45.36" upper_limit="-33.32"/>
                    <measurement group_id="O2" value="-31.43" lower_limit="-34.86" upper_limit="-28.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Weight Change</title>
        <description>Percent weight loss achieved before and after surgery while taking the medication, Qsymia.</description>
        <time_frame>Pre-operatively and 6 months post-operatively</time_frame>
        <population>2 participants had RYGB instead of sleeve gastrectomy</population>
        <group_list>
          <group group_id="O1">
            <title>Phentermine/Topiramate</title>
            <description>All subjects enrolled in the study will be placed on the study medication.
Phentermine/topiramate: Minimum of 3 months on Qsymia (7.5/46 mg) prior to scheduled weight loss surgery and continuance of up to 24 months of Qsymia after scheduled weight loss surgery.</description>
          </group>
          <group group_id="O2">
            <title>Surgery Only</title>
            <description>Historical controls who had surgery only</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Weight Change</title>
          <description>Percent weight loss achieved before and after surgery while taking the medication, Qsymia.</description>
          <population>2 participants had RYGB instead of sleeve gastrectomy</population>
          <units>Percent</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-32.79" lower_limit="-37.56" upper_limit="-28.02"/>
                    <measurement group_id="O2" value="-27.25" lower_limit="-29.97" upper_limit="-24.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Weight Change</title>
        <description>Percent weight loss achieved before and after surgery while taking the medication, Qsymia.</description>
        <time_frame>Pre-operatively and 3 months post-operatively</time_frame>
        <population>2 participants had RYGB instead of sleeve gastrectomy</population>
        <group_list>
          <group group_id="O1">
            <title>Phentermine/Topiramate</title>
            <description>All subjects enrolled in the study will be placed on the study medication.
Phentermine/topiramate: Minimum of 3 months on Qsymia (7.5/46 mg) prior to scheduled weight loss surgery and continuance of up to 24 months of Qsymia after scheduled weight loss surgery.</description>
          </group>
          <group group_id="O2">
            <title>Surgery Only</title>
            <description>Historical controls who had surgery only</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Weight Change</title>
          <description>Percent weight loss achieved before and after surgery while taking the medication, Qsymia.</description>
          <population>2 participants had RYGB instead of sleeve gastrectomy</population>
          <units>Percent</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-25.24" lower_limit="-29.63" upper_limit="-20.84"/>
                    <measurement group_id="O2" value="-21.46" lower_limit="-23.96" upper_limit="-18.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Body Mass Index</title>
        <description>Resulting body mass index</description>
        <time_frame>12 months post-operatively</time_frame>
        <population>2 participants had RYGB instead of Sleeve gastrectomy</population>
        <group_list>
          <group group_id="O1">
            <title>Phentermine/Topiramate</title>
            <description>All subjects enrolled in the study will be placed on the study medication.
Phentermine/topiramate: Minimum of 3 months on Qsymia (7.5/46 mg) prior to scheduled weight loss surgery and continuance of up to 24 months of Qsymia after scheduled weight loss surgery.</description>
          </group>
          <group group_id="O2">
            <title>Surgery Only</title>
            <description>Historical controls who had surgery only</description>
          </group>
        </group_list>
        <measure>
          <title>Body Mass Index</title>
          <description>Resulting body mass index</description>
          <population>2 participants had RYGB instead of Sleeve gastrectomy</population>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.46" lower_limit="29.94" upper_limit="36.98"/>
                    <measurement group_id="O2" value="39.53" lower_limit="37.43" upper_limit="41.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Body Mass Index</title>
        <description>Resulting body mass index</description>
        <time_frame>6 months post-operatively</time_frame>
        <population>2 participants had RYGB instead of Sleeve gastrectomy</population>
        <group_list>
          <group group_id="O1">
            <title>Phentermine/Topiramate</title>
            <description>All subjects enrolled in the study will be placed on the study medication.
Phentermine/topiramate: Minimum of 3 months on Qsymia (7.5/46 mg) prior to scheduled weight loss surgery and continuance of up to 24 months of Qsymia after scheduled weight loss surgery.</description>
          </group>
          <group group_id="O2">
            <title>Surgery Only</title>
            <description>Historical controls who had surgery only</description>
          </group>
        </group_list>
        <measure>
          <title>Body Mass Index</title>
          <description>Resulting body mass index</description>
          <population>2 participants had RYGB instead of Sleeve gastrectomy</population>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.61" lower_limit="34.83" upper_limit="40.38"/>
                    <measurement group_id="O2" value="41.93" lower_limit="40.23" upper_limit="43.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Body Mass Index</title>
        <description>Resulting body mass index</description>
        <time_frame>3 months post-operatively</time_frame>
        <population>2 participants had RYGB instead of Sleeve gastrectomy</population>
        <group_list>
          <group group_id="O1">
            <title>Phentermine/Topiramate</title>
            <description>All subjects enrolled in the study will be placed on the study medication.
Phentermine/topiramate: Minimum of 3 months on Qsymia (7.5/46 mg) prior to scheduled weight loss surgery and continuance of up to 24 months of Qsymia after scheduled weight loss surgery.</description>
          </group>
          <group group_id="O2">
            <title>Surgery Only</title>
            <description>Historical controls who had surgery only</description>
          </group>
        </group_list>
        <measure>
          <title>Body Mass Index</title>
          <description>Resulting body mass index</description>
          <population>2 participants had RYGB instead of Sleeve gastrectomy</population>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.31" lower_limit="39.78" upper_limit="44.84"/>
                    <measurement group_id="O2" value="45.28" lower_limit="43.71" upper_limit="46.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Body Fat</title>
        <description>Change in percent body fat</description>
        <time_frame>12 months post-operatively</time_frame>
        <population>Measure not obtained</population>
        <group_list>
          <group group_id="O1">
            <title>Phentermine/Topiramate</title>
            <description>All subjects enrolled in the study will be placed on the study medication.
Phentermine/topiramate: Minimum of 3 months on Qsymia (7.5/46 mg) prior to scheduled weight loss surgery and continuance of up to 24 months of Qsymia after scheduled weight loss surgery.</description>
          </group>
          <group group_id="O2">
            <title>Historical Control</title>
            <description>Historical controls who had sleeve gastrectomy during the same time frame without phentermine/topiramate treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Body Fat</title>
          <description>Change in percent body fat</description>
          <population>Measure not obtained</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Body Fat</title>
        <description>Change in percent body fat</description>
        <time_frame>6 months post-operatively</time_frame>
        <population>Measure not obtained</population>
        <group_list>
          <group group_id="O1">
            <title>Phentermine/Topiramate</title>
            <description>All subjects enrolled in the study will be placed on the study medication.
Phentermine/topiramate: Minimum of 3 months on Qsymia (7.5/46 mg) prior to scheduled weight loss surgery and continuance of up to 24 months of Qsymia after scheduled weight loss surgery.</description>
          </group>
          <group group_id="O2">
            <title>Historical Control</title>
            <description>Historical controls who had sleeve gastrectomy during the same time frame without phentermine/topiramate treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Body Fat</title>
          <description>Change in percent body fat</description>
          <population>Measure not obtained</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Body Fat</title>
        <description>Change in percent body fat</description>
        <time_frame>3 months post-operatively</time_frame>
        <population>Measure not obtained</population>
        <group_list>
          <group group_id="O1">
            <title>Phentermine/Topiramate</title>
            <description>All subjects enrolled in the study will be placed on the study medication.
Phentermine/topiramate: Minimum of 3 months on Qsymia (7.5/46 mg) prior to scheduled weight loss surgery and continuance of up to 24 months of Qsymia after scheduled weight loss surgery.</description>
          </group>
          <group group_id="O2">
            <title>Historical Control</title>
            <description>Historical controls who had sleeve gastrectomy during the same time frame without phentermine/topiramate treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Body Fat</title>
          <description>Change in percent body fat</description>
          <population>Measure not obtained</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Resting Metabolic Rate</title>
        <description>Resting metabolic rate via indirect calorimetry</description>
        <time_frame>12 months post-operatively</time_frame>
        <population>Outcome measure not obtained</population>
        <group_list>
          <group group_id="O1">
            <title>Phentermine/Topiramate</title>
            <description>All subjects enrolled in the study will be placed on the study medication.
Phentermine/topiramate: Minimum of 3 months on Qsymia (7.5/46 mg) prior to scheduled weight loss surgery and continuance of up to 24 months of Qsymia after scheduled weight loss surgery.</description>
          </group>
          <group group_id="O2">
            <title>Surgery Only</title>
            <description>Historical controls who had surgery only</description>
          </group>
        </group_list>
        <measure>
          <title>Resting Metabolic Rate</title>
          <description>Resting metabolic rate via indirect calorimetry</description>
          <population>Outcome measure not obtained</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Resting Metabolic Rate</title>
        <description>Resting metabolic rate via indirect calorimetry</description>
        <time_frame>6 months post-operatively</time_frame>
        <population>Outcome measure not obtained</population>
        <group_list>
          <group group_id="O1">
            <title>Phentermine/Topiramate</title>
            <description>All subjects enrolled in the study will be placed on the study medication.
Phentermine/topiramate: Minimum of 3 months on Qsymia (7.5/46 mg) prior to scheduled weight loss surgery and continuance of up to 24 months of Qsymia after scheduled weight loss surgery.</description>
          </group>
          <group group_id="O2">
            <title>Surgery Only</title>
            <description>Historical controls who had surgery only</description>
          </group>
        </group_list>
        <measure>
          <title>Resting Metabolic Rate</title>
          <description>Resting metabolic rate via indirect calorimetry</description>
          <population>Outcome measure not obtained</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Resting Metabolic Rate</title>
        <description>Resting metabolic rate via indirect calorimetry</description>
        <time_frame>3 months post-operatively</time_frame>
        <population>Outcome measure not obtained</population>
        <group_list>
          <group group_id="O1">
            <title>Phentermine/Topiramate</title>
            <description>All subjects enrolled in the study will be placed on the study medication.
Phentermine/topiramate: Minimum of 3 months on Qsymia (7.5/46 mg) prior to scheduled weight loss surgery and continuance of up to 24 months of Qsymia after scheduled weight loss surgery.</description>
          </group>
          <group group_id="O2">
            <title>Surgery Only</title>
            <description>Historical controls who had surgery only</description>
          </group>
        </group_list>
        <measure>
          <title>Resting Metabolic Rate</title>
          <description>Resting metabolic rate via indirect calorimetry</description>
          <population>Outcome measure not obtained</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>24 months</time_frame>
      <desc>Adverse events ascertained at each clinical follow up. Retrospective chart review patients were not considered enrolled, so adverse event information was not collected for them.</desc>
      <group_list>
        <group group_id="E1">
          <title>Phentermine/Topiramate</title>
          <description>All subjects enrolled in the study will be placed on the study medication.
Phentermine/topiramate: Minimum of 3 months on Qsymia (7.5/46 mg) prior to scheduled weight loss surgery and continuance of up to 24 months of Qsymia after scheduled weight loss surgery.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Panniculitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>insomnia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>irritability</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>This was an open-label, nonrandomized observational trial of only 2 years postoperative follow-up.
We also did not control for the amount of contact that patients received in the course of their treatment.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Jamy Ard</name_or_title>
      <organization>Wake Forest School of Medicine</organization>
      <phone>336-716-9837</phone>
      <email>jard@wakehealth.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

